Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
2.2500
-0.6000 (-21.05%)
Biodexa Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies for the treatment of cancer and other serious diseases
The company specializes in developing proprietary drug delivery systems designed to enhance the therapeutic efficacy of existing drugs while minimizing side effects. By leveraging its expertise in nanomedicine and targeted delivery technologies, Biodexa strives to create safer, more effective treatment options to improve patient outcomes in oncology and beyond.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.
Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer, with significant improvements in survival rates in Phase 1 trials.
Biodexa Pharmaceuticals shares are soaring in Tuesday's after-hours session after the company announced it was granted an extension to demonstrate compliance with Nasdaq listing requirements.
